Streetbeat News

BTMD

biote Corp.

https://biote.com

Industry

Medical - Care Facilities

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Open

6.59

Mkt cap

293M

Volume

484K

High

6.59

P/E Ratio

10.78

52-wk high

8.44

Low

5.26

Div yield

N/A

52-wk low

3.65

Biote shares dropped significantly after J Capital issued a report on the company, announcing a short position.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:18 pm

Biote has reaffirmed its 2024 financial guidance, citing a strong first quarter and expectations for increased revenue growth in the latter half of the year. The company expects revenues to be between $200-$204 million and adjusted EBITDA to be in the range of $60-$63 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 10:15 pm

Biote (NASDAQ:BTMD) reported Q1 2024 earnings with a GAAP EPS of $(0.06), missing the $0.03 estimate, but sales of $46.804M exceeded the $45.711M forecast. This represents a significant improvement in losses and a slight increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 9:48 pm

Biote Corp. (NASDAQ:BTMD) has reached a settlement with its founder, Dr. Gary S. Donovitz, to repurchase 18.4 million shares at $4.17 per share, totaling approximately $76.9 million. This settlement resolves ongoing litigation and includes a mutual release of claims, termination of the founder advisory agreement, and non-compete and non-solicitation agreements. The repurchase is structured over a three-year period, with the first transaction of approximately $32.2 million completed on April 26, 2024. Biote believes this action will be accretive to shareholder value and allows the company to focus on strategic objectives and growth.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:20 pm

In Friday's after-market session, several healthcare stocks showed significant movement. Notably, Qilian Intl Hldg Gr, Sunshine Biopharma, and Galera Therapeutics were among the top gainers, with Qilian Intl leading with a 63.8% increase. On the downside, Vivos Therapeutics, ENDRA Life Sciences, and Applied Therapeutics experienced notable declines, with Vivos Therapeutics dropping 22.4%. The movements were largely attributed to the release of Q4 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

March 29, 2024 | 8:30 pm

Biote shares have experienced an increase in trading volume and price following the announcement of their Q4 GAAP EPS results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:52 pm

Roth MKM analyst George Kelly has reiterated a Buy rating on Biote (NASDAQ:BTMD) and increased the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 3:12 pm

Biote has reaffirmed its 2024 financial guidance, expecting revenues between $200M-$204M and Adjusted EBITDA between $60M-$63M. The company anticipates low-single digit revenue growth in H1 2024, with a significant improvement in H2, attributed to changes in the nutraceutical distribution channel and seasonal promotions.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:52 pm

Biote (NASDAQ:BTMD) reported Q4 earnings with an EPS of $0.18, surpassing the estimate of $0.08 by 125%. Revenue increased by $1.22 million year-over-year. Despite beating EPS estimates in the past, such as in Q3 2023, the share price dropped 24% the following day.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:15 pm

Biote (NASDAQ:BTMD) reported Q4 2023 earnings of $0.18 per share, surpassing the $0.08 estimate, but its sales of $45.703M slightly missed the $45.740M estimate. Year-over-year, earnings remained stable while sales grew by 2.74%.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.